The tumor microenvironment is considered to play an important role in tumor formation and progression by providing both negative and positive signals that influence tumor cell growth.
INTRODUCTION
Neurofibromatosis 1 (NF1) is an autosomal dominant tumor predisposition syndrome affecting 1 in 3500 individuals worldwide (1) . The most common tumors that develop in the context of NF1 occur in the peripheral and central nervous system. Tumors of the peripheral nerves (neurofibromas) typically arise in young adults and are composed of neoplastic NF1-deficient Schwann cells and NF1+/-fibroblasts, mast cells, and vascular elements (2, 3) . Within the central nervous system, children with NF1 are prone to the development of low-grade glial tumors (4) . These glial cell tumors are classified by the World Health Organization (WHO) as grade I astrocytomas (pilocytic astrocytoma) and are most commonly located in the optic pathway and hypothalamus (5, 6) . In contrast to sporadic pilocytic astrocytomas arising in children without NF1, NF1-associated pilocytic astrocytoma typically behave in a clinically less aggressive fashion, rarely progress beyond 10 years of age in children, and have been reported to regress without treatment (7) (8) (9) (10) .
Since the management of NF1-associated glioma does not usually involve surgical resection or biopsy, there are limited opportunities to define the molecular and cellular basis for glioma formation in humans. For this reason, recent studies have focused on the use of geneticallyengineered mice in which Nf1 gene inactivation occurs in astroglial cells. Previous work has shown that homozygous Nf1 inactivation in astroglial cells results in increased astrocyte growth in vitro and in vivo, but is insufficient for glioma formation in mice (11) . However, geneticallyengineered mice with targeted astroglial loss of neurofibromin expression in the context of an Nf1+/-heterozygous brain environment develop optic glioma by 2-3 months of age (12) (13) (14) .
These findings raise the intriguing possibility that Nf1+/-cells in the tumor microenvironment might influence Nf1-deficient astrocyte proliferation relevant to glioma formation and growth.
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RESULTS
Nf1+/-microglia exhibit increased proliferation compared to wild-type microglia
To determine whether infiltrating microglia were found in both human NF1-associated pilocytic astrocytomas and in a genetically-engineered mouse model of Nf1 optic glioma, we performed immunohistochemistry to identify microglia in paraffin tumor sections. We found infiltrating microglia in all five representative Nf1 mouse optic glioma specimens ( Figure 1B ), but not in wild-type mouse optic nerves ( Figure 1A ). Microglia were also present in all human NF1-associated pilocytic astrocytomas examined (n=5) ( Figure 1D ). Since the microglia in these tumors could represent either postnatal bone marrow-derived monocytes (CD45+ macrophages) or resident microglia (CD68+, CD45-cells) which populate the brain during embryonic development (20) (21) (22) , we immunostained the human NF1-associated pilocytic astrocytomas with CD68 and CD45 antibodies, and found that the infiltrating microglia were CD68+ ( Figure   1D )/CD45-( Figure 1C ) resident brain microglia. Similarly, CD68+/CD45-microglia were identified in the mouse optic gliomas (data not shown). Positive controls for CD45 staining are shown for both human and mouse optic gliomas ( Figure 1E and 1F), respectively.
To provide direct evidence for an effect of Nf1 heterozygosity on microglia proliferation, we isolated brain microglia from postnatal day 1-2 Nf1+/-and wild-type littermates using established techniques (23) . These primary microglia cultures were assessed for viability and cellular composition using immunocytochemistry with a rat monoclonal antibody directed against CD68, a specific cell surface marker of resident brain microglia, as well as GFAP, a marker for astrocytes. Over 98% of the cells in the microglia cultures were CD68+ microglia with few contaminating astrocytes (Figure 2A ). Similar to the microglia present in the human 7 proliferation of Nf1-/-or Nf1+/+ astrocytes. We also performed experiments in which the percentage of microglia were varied in the co-cultures, and found that Nf1+/-microglia increased Nf1-/-astrocyte proliferation over a range from 1% to 10% ( Figure 3B ). While the differences were not statistically significant, we observed a trend towards increased Nf1-/-astrocyte proliferation in response to increasing numbers of microglia (1.25 fold with 1% microglia compared to 1.4 fold with 5-10% microglia).
To demonstrate that the effects of Nf1+/-microglia co-culture on Nf1-/-astrocytes were due to increased Nf1-/-astrocyte proliferation, we performed BrdU incorporation experiments in vitro. Astrocyte-microglia co-cultures were immunostained with anti-BrdU, anti-GFAP, and anti-CD68 antibodies. In the co-cultures, there were increased numbers of GFAP/BrdU doublepositive cells in the co-cultures containing Nf1+/-microglia compared to co-cultures with Nf1+/+ microglia ( Figure 3C ). No increase in microglia proliferation was observed in response to astrocyte co-culture under these conditions, and the increase in BrdU incorporation observed reflected astrocyte proliferation in these cultures. These findings indicate that Nf1+/-microglia enhance Nf1-/-astrocyte proliferation.
Nf1+/-microglia-conditioned medium enhances astrocyte proliferation
We next sought to determine whether soluble paracrine factors produced by Nf1+/-microglia increased Nf1-/-astrocyte proliferation. Microglia conditioned medium (CM) was obtained by collecting cell culture supernatants from microglia grown for 5 days. Supernatants were concentrated 30-fold using Centriplus concentrators. Microglia CM was then added to serum-starved Nf1-/-and Nf1+/+ astrocytes, and proliferation measured by [ 3 H] thymidine incorporation. In these experiments, the addition of Nf1+/-microglia CM increased Nf1-/-8 astrocyte proliferation by 1.5 fold, similar to that observed in the co-culture experiments ( Figure   3D ). In contrast, Nf1+/+ microglia CM had no effect on Nf1-/-astrocyte proliferation. These results demonstrate that Nf1+/-microglia produce soluble factors that uniquely increase the proliferation of Nf1-/-astrocytes.
Nf1+/-microglia-induced Nf1-/-astrocyte proliferation is mediated by hyaluronidase insulin-like growth factor-1 (IGF-1) and hepatocyte growth factor/scatter factor (HGF), and hyaluronidase (Table 1) . We chose to focus on PTN, IGF-1, HGF, and hyaluronidase in functional validation studies, based on previous studies implicating these factors in promoting cell growth (28) (29) (30) .
In these experiments, we examined the ability of these candidates to increase Nf1-/-astrocyte proliferation, as measured by [ 3 H] thymidine incorporation. Hepatocyte growth factor (HGF), insulin-like growth factor (IGF-1), pleiotrophin (PTN), and hyaluronidase were each analyzed over a concentration range on Nf1-/-and Nf1+/+ astrocytes (10-100 ng/ml for HGF, IGF-1, and PTN; 10-100 U/ml for hyaluronidase). Under the experimental conditions used, PTN had no effect on either Nf1+/+ and Nf1-/-astrocyte proliferation, while HGF and IGF caused modest increases in thymidine incorporation of both Nf1+/+ and Nf1-/-astrocytes (1.2 fold increase; 9 data not shown). In contrast, hyaluronidase at a concentration of 50 units/ml resulted in increased Nf1-/-astrocyte proliferation ( Figure 4A ). At this concentration, we observed no effect of hyaluronidase on wild-type astrocyte proliferation. We observed similar results in three independent experiments, and the results from one representative experiment are shown.
To determine whether hyaluronidase accounted for the growth-promoting effects of Nf1+/-microglia CM on Nf1-/-astrocyte proliferation, we employed two different established inhibitors of hyaluronidase activity, polystyrene-4-sulfonate (PSS; molecular weight 990,000) and heparin.
Both PSS and heparin have previously been shown to inhibit most hyaluronidases (31) . In these experiments, we found that PSS and heparin blocked the effect of Nf1+/-microglia CM on Nf1-/-astrocyte proliferation ( Figure 4B Figure 5C ). Similarly, treatment with U0126, heparin or PSS also blocked the hyaluronidase-induced increase in Nf1-/-astrocyte proliferation ( Figure 4D ).
To extend our findings to glioma growth, we found that hyaluronidase also increases the proliferation of high-grade human glioma (U87MG) cells as assayed by thymidine incorporation 
Hyaluronic acid binding protein (HABP) staining is decreased in both murine and human
NF1-associated optic pathway gliomas
To provide evidence for increased hyaluronidase activity in NF1-associated low-grade glioma, we employed hyaluronic acid (HA)-binding protein (HA-BP) histochemistry as a surrogate marker of hyaluronidase activity in situ. HA-BP binds to HA normally present in brain tissue; however, in the presence of hyaluronidase, there is reduced HA-BP immunoreactivity.
We analyzed HA-BP staining in murine Nf1 optic glioma specimens from genetically-engineered mice (n=4). There was significantly decreased HA-BP immunostaining in all murine Nf1 optic gliomas ( Figure 6C and 6D) compared to optic nerves from wild-type mice ( Figure 6A ) or mice lacking neurofibromin expression in astrocytes (Nf1 GFAP CKO mice; Figure 6B ). Similar experiments using human NF1-associated pilocytic astrocytoma specimens also revealed decreased HA-BP immunostaining relative to normal human brain (data not shown). These results provide in vivo evidence for a relationship between increased hyaluronidase activity and NF1-associated glioma.
Next, we sought to determine the relative expression of hyaluronidase in microglia freshly isolated from the brains of postnatal day 10 Nf1+/+ and Nf1+/-mice using the Percoll density gradient method (35, 36) . We chose this method to obtain microglia directly from the brain without any growth in vitro. Since there are no hyaluronidase antibodies suitable for immunohistochemistry and we were unable to measure hyaluronidase expression in Nf1+/+ and Nf1+/-microglia culture supernatants using a hyaluronidase ELISA-like assay (data not shown),
we performed quantitative RT-PCR using SYBR Green chemistry on RNA samples from these brain microglia. We found a two-fold increase in hyaluronidase RNA expression in Nf1+/-microglia compared to Nf1+/+ microglia ( Figure 6E ), demonstrating that Nf1+/-microglia express increased hyaluronidase in vivo.
Minocycline-mediated microglia inactivation results in decreased optic glioma proliferation in vivo
Previous studies have shown that minocycline inhibits microglial activation in several animal models of neurodegenerative disease (37) (38) (39) ; GFAP-Cre (OPG) mice. Thirty days after the completion of minocycline treatment, mice were injected with BrdU and the optic nerves were removed 2 hours later for analysis. We observed a 3-fold decrease in BrdU-labeled cells in the optic gliomas from minocycline-treated mice compared to vehicle-treated mice ( Figure 7A and 7B). Since the processing for BrdU immunocytochemistry precludes the use of DAPI staining to identify total cell number, we employed CREB immunohistochemistry to identify the nuclei in the minocycline-and vehicle-treated mouse optic nerves ( Figure 7A ; middle panels). Based on previous experiments, the reduction in proliferation observed after minocycline treatment is similar to that observed in 3 month old optic nerves from control mice (13) .
We next sought to determine whether minocycline decreased the optic glioma proliferation by inhibiting microglia activation. Since there are no antibodies to accurately identify activated microglia, we employed a surrogate morphologic measure of microglia activation (38, (40) (41) (42) .
We found more CD68+ microglia with small cell bodies and thin and ramified processes (resting microglia) in the minocycline-treated mice compared to the vehicle-treated mice ( Figure 7A ). In contrast, vehicle-treated mice had more activated amoeboid-shaped CD68+ microglia with large cell bodies. We counted both activated amoeboid shaped microglia and inactivated ramified microglia in the minocycline and vehicle injected animals. We found a ~3-fold decrease in the number of activated microglia in the optic nerves from minocycline-treated mice (83% activated microglia) compared to vehicle-injected mice (23% activated microglia).
In addition to its effects on microglia activation, minocycline has been reported to affect angiogenesis (43, 44) . Since both human and genetically-engineered mouse optic glioma exhibit increased microvascular proliferation (6, 13), we determined the effect of minocycline on minocycline (data not shown). Moreover, minocycline had no effect on either Nf1+/-microglia or Nf1-/-astrocyte proliferation in vitro (data not shown).
Collectively, these findings provide in vivo evidence that tumoral microglia provide key growth-promoting signals for Nf1-/-optic glioma astrocytes.
DISCUSSION
The interaction between neoplastic cells and the non-neoplastic cellular elements in the tumor microenvironment is an important step in tumor progression (45, 46) . These findings suggested that Nf1+/-microglia might promote Nf1-/-astrocyte proliferation through the elaboration of paracrine factors. To define the contribution of these Nf1+/-cells to optic glioma formation, we examined the role of Nf1+/-microglia in promoting Nf1-deficient astrocyte growth.
We found that Nf1+/-microglia exhibit a growth advantage relative to wild-type microglia in response to microglia mitogens (e.g., colony stimulating factor) as well as to serum factors.
The increased proliferation of Nf1+/-microglia is significant in light of reports that pilocytic astrocytomas, the histologic astrocytoma subtype seen in children with NF1, have the highest rates of proliferating microglia among all malignancy grades of astrocytoma (57) . It is important to note that the hyperproliferating Nf1+/-microglia found in both the human and geneticallyengineered mouse gliomas are resident CD68(+), CD45(-) microglia which populate the brain during embryogenesis (20, 22 Hyaluronidase is a compelling stroma-derived candidate growth regulator for astrocytes.
Recent studies have shown that hyaluronidase injection into the rodent spinal cord results in increased astrocyte proliferation (30) and that manipulations which increase hyaluronic acid synthesis decrease glioma growth in vivo (64) . While future studies will be required to define the mechanism underlying hyaluronidase-mediated proliferation in Nf1-/-astrocytes, we show that hyaluronidase treatment results in increased MAPK signaling and that pharmacologic inhibition of MAPK activation ameliorates the growth-promoting properties of hyaluronidase on Nf1-/-astrocytes. This is consistent with previous studies demonstrating that neurofibromin negatively regulates the RAS/MAPK pathway in multiple cell types (32-34).
We recognize that the effects of Nf1+/-microglia and hyaluronidase treatment on Nf1-/-astrocyte proliferation in vitro are modest. In this regard, it is unlikely that Nf1+/-microgliaproduced hyaluronidase is the sole rate-limiting determinant of glioma formation in NF1. We Moreover, the fact that Nf1+/-microglia produce paracrine factors that regulate Nf1-deficient astrocyte growth raises the intriguing possibility that additional therapies for NF1-associated tumors may target cells or factors present in the tumor microenvironment.
MATERIALS AND METHODS
Mouse and Human Specimens
Mice were used in accordance with established Animal Studies Protocols at the Washington 
Primary microglia cultures
Mixed glial cultures were prepared from postnatal day 1-2 pups. Primary murine microglia were isolated from mixed glial cultures by mild trypsinization as described previously (23) . Briefly, 15-20 day mixed glial cultures in 6 well plates were trypsinized with 0.05% trypsin -EDTA and intact layer of astrocytes was detached and removed. Microglia attached to the wells were recovered by trypsinization with 0.25% trypsin and vigorous pipetting.
Primary astrocyte cultures
Murine cortical astroglial cultures, containing glial fibrillary acidic protein (GFAP) positive cells (astrocytes), were generated from postnatal day 1-2 Nf1 flox/flox pups as previously described (11). 
Microglia-astrocyte cultures
Nf1+/+ and Nf1-/-astrocytes were seeded at 50,000 cells/well in 24-well plates. After 24 hrs, primary microglia were isolated and seeded on top of the astrocytes at a density of 1, 5 and 10% of total astrocytes. Co-cultures were grown for an additional 3 days. Proliferation was measured after 24 hours of serum starvation by BrdU and [ 3 H] thymidine incorporation.
Conditioned medium
Primary microglia were grown in mixed glial conditioned medium. Every 24 hrs, medium was collected from microglia and the cultures were then replenished with fresh medium. Conditioned medium from four media changes was pooled and concentrated 30-fold by Millipore Centriplus filtration. 
Proliferation assays
ELISA-like assay for hyaluronidase activity
Hyaluronidase activity was determined by an ELISA-like assay as described previously (69, 70).
96-well microtiter plates were coated with 200ug/ml human umbilical cord hyaluronic acid in sodium carbonate buffer. Microglia cell culture supernatants or Streptomyces hyaluronidase or testicular hyaluronidase were incubated in HA-coated wells in sodium formate assay buffer at 37º C for 18 hrs. The wells were then washed with PBS-Tween buffer and incubated with 1μg/ml biotinylated HA-binding protein at 37º C for 2hrs. After washing, the amount of HA remaining in the wells was quantified using the Elite ABC detection kit (Vector Labs, Burlingame, CA). The absorbance was read at 405 nm in a microtiter plate reader. A standard graph was obtained by using absorbance of Streptomyces hyaluronidase or testicular hyaluronidase. The mean hyaluronidase activity in cell culture supernatants was calculated using the standard graph. All the reagents were obtained from Sigma (Saint Louis, MO).
HA-BP histochemistry
For HA-BP staining of optic nerves and brain, mice were perfused transcardially with ice-cold PBS and fixed with 4% paraformaldehyde. The optic nerves and brains were dissected, fixed, and processed for paraffin embedding and sectioning. 5 µm paraffin-embedded sections of mouse optic nerves were deparaffinized followed by antigen retrieval in EDTA buffer. The sections were then incubated with 2µg/ml biotinylated HA-BP (Sigma, St. Louis, MO) overnight at 4º C. On the following day, sections were washed in PBS and incubated with strepavidinconjugated Cy-3 antibodies (1:500 dilution; Jackson lab, West Grove, PA) for 1 hr at room temperature. Sections were washed and then analyzed and photographed with a digital camera (Optronics, Goleta, CA) attached to an inverted microscope (Nikon, Melville, NY).
Microarray gene expression profiling
Analysis was performed by the Siteman Cancer Center Multiplexed Gene Analysis Core Facility.
For the expression profiling experiments, we generated four sets of primary microglia samples: annotated, MIAME-compliant data set can be found at the above noted URL. Probe sets that were absent across all chips were filtered from the analysis. Basic microarray data visualization and data filtering were performed using Spotfire Decision site for Functional Genomics (Somerville, MA).
Microglia isolation from mouse brains
Cerebral hemispheres directly isolated from postnatal 10 day mice were homogenized, passed through a 40 µM nylon cell strainer (BD Biosciences, Bedford, MA), and separated by Percoll gradient centrifugation according to established protocols (35, 36) .
Real-time RT-PCR
Total RNA was extracted from freshly-isolated microglia using Trizol reagent as recommended by manufacturer (Invitrogen, Carlsbad, CA). cDNA was synthesized from total RNA samples using Omniscript kit (Qiagen, Valencia, CA). Real-time PCR was performed using the SYBR Green (Applied Biosystems, Foster city, CA) detection according to manufacturer's instructions.
Target amplification was performed in 96 well plates in a real-time sequence detection system instrument (ABI PRISM 9700HT, Applied Biosystems). The primer set used for hyaluronidase was: (S) 5'-GATGACTGT AAAGCGCACCCA-3 ٰ' and (AS) 5'ٰ -CACAAGACCCAAAGAGGAGCA-3 ٰ'. SDS system software was used to convert the fluorescent data into cycle threshold (CT) measurements. The ΔΔCT method was used to calculate changes in fold expression relative to Nf1+/+ microglia using β-actin as internal control (71).
Minocycline treatment
Minocycline hydrochloride (Sigma, St. Louis, MO) was dissolved in phosphate-buffered saline and administered at dosage of 50mg/ kg consecutively for 7 days. Mice were divided into two groups: one received intraperitoneal injections of minocycline and the other received injections of vehicle (sterile phosphate-buffered saline). There were five animals in each group. Thirty days after the injection, mice were euthanized by transcardiac perfusion with normal saline followed by 4% paraformaldehyde for preparation of paraffin-embedded optic nerve sections. In vivo proliferation was measured by BrdU labeling.
In vivo BrdU labeling and immunohistological analysis
For in vivo cell proliferation experiments, minocycline and saline injected animals were injected with BrdU (50 mg/ kg). Two hours after BrdU injection animals were perfused transcardially with ice-cold PBS and fixed with 4% paraformaldehyde. The optic nerves were dissected, fixed, and processed for paraffin embedding and sectioning. 5µm paraffin-embedded sections of mouse optic nerves were deparaffinized followed by antigen retrieval in EDTA buffer. DNA denaturation was done by 0.1% trypsin treatment, followed by 4N HCl for 30 min at 37º C , followed by neutralization with 0.1M sodium borate buffer, pH 8.5, for 5 min. Sections were blocked with 5% goat serum for 1 hr at room temperature, followed by incubation with rat antiBrdU antibody (Abcam, Cambridge, MA) overnight at 4º C. Sections were next washed in PBSTween and incubated with Goat Oregon Green 488 for 1 hr at room temperature. Finally, sections were washed, mounted with Vectashield mounting medium and analyzed under microscope. The number of BrdU+ cells were determined as previously described (13) . CREB immunohistochemistry was performed using a commercial CREB antibody (9197, 1:100 dilution; Cell Signaling Technology, Beverly, MA).
Western blot analysis
Western blots were performed as described previously (24 
Statistical analysis
Student's t-test was used with significance set at P < 0.05. All experiments were performed at least three times with similar results. Real-time quantitative PCR demonstrates a two-fold increase in hyaluronidase RNA expression in Nf1+/-microglia compared to Nf1+/+ microglia directly isolated from postnatal 10 day mouse brains. The asterisk denotes a statistically significant difference (P<0.05).
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